Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
161 participants
INTERVENTIONAL
2009-07-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. high-dose furosemide (HDF, 40 mg furosemide bolus IV, followed by continuous IV infusion of 20 mg/h for a total of 8 hours),
2. low-dose furosemide (LDF, 40 mg furosemide bolus IV, followed by continuous IV infusion of 5 mg/h furosemide for a total of 8 hours), and
3. low-dose furosemide combined with low-dose dopamine (LDFD, 40 mg furosemide bolus IV, followed by continuous IV infusion of 5 mg/h furosemide plus 5μg/kg/min dopamine for a total of 8 hours) on diuresis, perceived dyspnea, renal function, electrolyte balance, total length of stay, and 60-day post-discharge outcomes in patients hospitalized with ADHF.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High-dose furosemide
High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
High-dose furosemide
High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
Low-dose furosemide
Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
Low-dose furosemide
Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
Low-dose furosemide combined with low-dose dopamine
Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
Low-dose furosemide combined with low-dose dopamine
Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High-dose furosemide
High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
Low-dose furosemide
Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
Low-dose furosemide combined with low-dose dopamine
Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signs of congestion (third heart sound or pulmonary rales on physical examination),
* pulmonary congestion on chest x-ray,
* serum B-type natriuretic peptide levels \> 400 pg/ml or NT-proBNP \> 1500 pg/ml,
* echocardiographic documentation of systolic or diastolic dysfunction,
* age \>18 years old,
* on medical therapy with an ACE-inhibitor and/or a β-blocker,
* experiencing an acute decompensation of known chronic HF,
* baseline oxygen saturation \<90% on admission arterial blood gas
Exclusion Criteria
* severe renal failure (serum creatinine \>200 μmol/L or GFR \<30 ml/min/1.73m2)
* admission systolic blood pressure \<90 mm Hg;
* severe valvular disease;
* known adverse reactions to furosemide or dopamine;
* HF secondary to congenital heart disease;
* a scheduled procedure with a need for IV contrast dye;
* a scheduled cardiac surgery within 6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Larissa University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gregory Giamouzis
Assistant Professor of Cardiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregory Giamouzis, MD
Role: STUDY_CHAIR
Department of Cardiology, Larissa University Hospital, Larissa, Greece
Filippos Triposkiadis, MD
Role: STUDY_CHAIR
Department of Cardiology, Larissa University Hospital, Larissa, Greece
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Cardiology, Emory University Hospital
Atlanta, Georgia, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
First Department of Cardiology, University of Athens
Athens, Attica, Greece
Department of Cardiology, Larissa University Hospital
Larissa, Larissa, Greece
Department of Cardiology, Volos General Hospital
Volos, Magnesia, Greece
AHEPA University Hospital
Thessaloniki, Thessaloniki, Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Triposkiadis FK, Butler J, Karayannis G, Starling RC, Filippatos G, Wolski K, Parissis J, Parisis C, Rovithis D, Koutrakis K, Skoularigis J, Antoniou CK, Chrysohoou C, Pitsavos C, Stefanadis C, Nastas J, Tsaknakis T, Mantziari L, Giannakoulas G, Karvounis H, Kalogeropoulos AP, Giamouzis G. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol. 2014 Mar 1;172(1):115-21. doi: 10.1016/j.ijcard.2013.12.276. Epub 2014 Jan 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3975
Identifier Type: -
Identifier Source: org_study_id